Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Accured Expenses (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Change in Accured Expenses for 6 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 200.25% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.2 million through Dec 2025, up 24.95% year-over-year, with the annual reading at $8.2 million for FY2025, 24.95% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $2.4 million at 4D Molecular Therapeutics, down from $5.0 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $8.1 million in Q3 2024, with the low at -$3.4 million in Q1 2023.
  • Average Change in Accured Expenses over 5 years is $1.1 million, with a median of $1.1 million recorded in 2021.
  • Peak annual rise in Change in Accured Expenses hit 1881.48% in 2021, while the deepest fall reached 339.27% in 2021.
  • Over 5 years, Change in Accured Expenses stood at $535000.0 in 2021, then surged by 240.75% to $1.8 million in 2022, then grew by 9.54% to $2.0 million in 2023, then plummeted by 218.48% to -$2.4 million in 2024, then skyrocketed by 200.25% to $2.4 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $2.4 million, $5.0 million, and $3.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.